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ABSTRACT
Tivantinib, a c-MET inhibitor, is investigated as a second-line treatment of HCC. 
It was shown that c-MET overexpression predicts its efficacy. Therefore, a phase-3 
trial of tivantinib has been initiated to recruit “c-MET-high”patients only. However, 
recent evidence indicates that the anticancer activity of tivantinib is not due to c-MET 
inhibition, suggesting that c-MET is a predictor of response to this compound rather than 
its actual target. By assessing the mechanisms underlying the anticancer properties of 
tivantinib we showed that this agent causes apoptosis and cell cycle arrest by inhibiting 
the anti-apoptotic molecules Mcl-1 and Bcl-xl, and by increasing Cyclin B1 expression 
regardless of c-MET status. However, we found that tivantinib might antagonize 
the antiapoptotic effects of c-MET activation since HGF enhanced the expression of 
Mcl-1 and Bcl-xl. In summary, we show that the activity of tivantinib is independent 
of c-MET and describe Mcl-1, Bcl-xl and Cyclin B1 as effectors of its antineoplastic 
effects in HCC cells. We suggest that the predictive effect of c-MET expression in part 
reflects the c-MET-driven overexpression of Mcl-1 and Bcl-xl in c-MET-high patients and 
that these molecules are considered as possible response predictors.
INTRODUCTION
Tivantinib (ARQ 197) is being investigated 
in clinical trials as selective orally available c-MET 
inhibitor [1]. Administered as a single agent in a 
second-line treatment setting, tivantinib was shown to 
prolong  significantly  the  time  to  progression  and  the 
survival of hepatocellular carcinoma (HCC) patients in 
a randomized, placebo-controlled, phase 2 clinical trial 
[2, 3]. Analysis of c-MET expression showed a clear 
advantage in overall survival in patients bearing tumors 
exhibiting a highly positive staining for c-MET but not in 
“MET-low” patients. The administration of tivantinib is 
thus regarded as a promising bona fide biomarker-based 
therapy of HCC. Consequently, patients’ selection in the 
ongoing phase 3 METIV-HCC trial of tivantinib is based 
on the detection of high expression of c-MET in tumor 
biopsies. The predictive value of c-MET in determining 
survival improvement in patients on tivaninib was recently 
confirmed  by  a  subgroup  analysis  of  a  randomized 
controlled trial in patients with non-squamous, non-small 
cell  lung  cancer  [4,  5]. Although  the  clinical  efficacy 
of tivantinib in c-MET-high patients in the two 
aforementioned trials suggests that its anticancer activity 
is determined by its capability to inhibit c-MET, several 
in vitro studies published very recently challenged this 
notion by showing that this compound exerts a remarkable 
cytotoxic effect in several cell lines without affecting the 
kinase activity of this receptor. These studies questioned 
the rationale for the use of this compound in c-MET-high 
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patients [6–9] and raised the issue of whether c-MET 
represents a response predictor of tivantinib rather than 
its actual target [10, 11]. In spite of the clinical relevance 
of this issue, the mechanisms of action of tivantinib as 
well as those determining the predictive value of c-MET 
expression still remain to be elucidated.
In the attempt to provide an answer to this 
question, we decided to investigate the so far still unclear 
intracellular mechanisms of action of tivantinib on cell 
death and cell cycle progression, and to assess how their 
regulation  is  influenced by  this  compound  in  cell  lines 
exhibiting different c-MET expression status [12, 13].
RESULTS
Tivantinib causes a strong loss of cell viability 
and of colony forming capability in a wide panel 
of cell lines from gastrointestinal tumors
The effect of tivantinib on cell viability was assessed 
in a wide panel of cell lines exhibiting different levels of 
c-MET expression including 4 HCC cell lines (Fig. 1A), 
one cholangiocellular carcinoma cell line, and three 
additional cancer cell lines from tumors of gastrointestinal 
origin (Fig. S1). Tivantinib caused a dose dependent loss 
of cell viability with IC50 values comprised between 
9.9 nM (Huh7) and 448 nM (Hep3B). These results 
were clearly confirmed by colony forming assays showing 
a reduction in the number and size of colonies in cells 
treated with tivantinib (Fig. 1B, Fig. S1B). As shown in 
Figure 1C-1D, the effect of tivantinib on phosphorylated 
c-MET was not evident in unstimulated cells due to 
low basal level of p-c-MET; however, administration of 
tivantinib with the c-MET ligand HGF caused a decrement 
of total c-MET as well as of its phosphorylated form in 
Huh7 or HepG2 cells (Fig. 1D). This phenomenon, which 
was also reported previously [6], shows that the effect 
of tivantinib on overall c-MET largely accounts for the 
observed decrease of c-MET phosphorylation.
Tivantinib enhances apoptosis by inhibiting the 
mitochondrial regulators of apoptosis  
Mcl-1 and Bcl-xl
To assess the mechanisms underlying the decrease 
in cell viability caused by tivantinib, we subsequently 
investigated its effect on apoptosis. As shown by the 
increasing sub-G1 cell fraction at FACS analysis after PI 
staining (Fig. 2A, S2A) tivantinib caused a dose- and time-
dependent increase of apoptosis. Induction of apoptosis was 
observable at the concentration of 533 nM and most cells 
showed features of apoptosis at a concentration of 1.6 μM 
after 48 hours of incubation (Fig. 2A) with chromatin 
condensation and nuclear fragmentation at Hoechst 
staining (Fig. 2C). Accordingly, progressive time- and 
dose-dependent increase of caspase 3 cleavage (Fig. 2D, 
S2B, S3A), increased caspase 3/7 activation (Fig. 2E, S3B) 
and cleavage of PARP (Fig. S3) were observed.
To further investigate the mechanisms underlying 
tivantinib-induced apoptosis, the effects of tivantinib on the 
two major pro-apoptotic signaling pathways-the extrinsic 
and the intrinsic apoptotic pathways-were assessed. Analysis 
of Caspase 8 showed a time and dose-dependent cleavage 
of Pro-caspase 8 and Bid (Fig. 2F), indicating an increased 
activation of the receptor-mediated apoptotic pathway. 
Accordingly, administration of tivantinib sensitized Huh7 
and HepG2 cells to the action of the TRAIL-R2 agonistic 
antibody tigatuzumab, which initiates the extrinsic 
apoptotic pathway dependently on Caspase 8 recruitment 
[14] (Fig. S4).
Analysis of the activation of the intrinsic apoptotic 
pathway showed that tivantinib additionally causes the 
downregulation of the antiapoptotic molecules Bcl-xl and 
Mcl-1 (Fig. 2F).
To assess the respective functional relevance of the 
extrinsic and intrinsic pathway activation in determining 
the effect of tivantinib, Huh7 cells were co-incubated 
with tivantinib and the Caspase 8 inhibitor Z-IETD-
FMK; as shown in Fig. 3A, inhibition of Caspase 8 only 
marginally reduced the proapoptotic effect of tivantinib. 
In contrast, silencing of Mcl-1 and Bcl-xl by simultaneous 
co-transfection of specific siRNA sequences in Huh7 cells 
led to a progressive increase of apoptosis and consequent 
loss of cell viability over 72 hours (Fig. 3B–3D). Analysis 
of cell cycle distribution in these samples showed no cell 
cycle arrest in consequence of Mcl-1 and Bcl-xl silencing 
(data not shown).
Due to the negligible effect of Caspase 8 inhibition 
on apoptosis, these data indicate that tivatinib induces 
apoptosis by shifting the balance between the pro- and 
anti-apoptotic mitochondrial regulators of the intrinsic 
signaling pathway (Fig. 2F).
Tivantinib-mediated accumulation of Cyclin B1 
is associated with a G2/M cell cycle arrest
Since tivantinib was reported to induce a G2-cell 
cycle arrest, we subsequently performed an analysis of the 
cell fraction in different phases of the cell cycle by FACS 
(Fig. 4A). Administration of tivantinib caused a G2/M cell 
cycle arrest in all cell lines assessed, with a corresponding 
decrease of the fraction of cells in G1 phase. For example, 
the fraction of cells in G1, S and G2/M phase in vehicle 
treated Huh7 cells were 57.9 ± 4.1%, 10.4 ± 5.9%, and 
31.7 ± 9.8% respectively. After 24 h incubation with 
tivantinib at the concentration of 1.6 μM the fractions of 
cells in the different phases of cell cycle were 24.1% ± 2.8, 
11.1 ± 2.0%, 64.9 ± 9.8% respectively (P < 0.01 - Fig. 4A). 
Similar effects were observed in several cell lines from 
colon cancer, cholangiocellular and pancreatic cancer 
cells (data not shown). To determine the mechanisms 
underlying the G2/M cell cycle arrest caused by tivantinib, 
expression of Cyclin B1, which is known to regulate 
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Figure 1: Tivantinib reduces cell viability and colony formation of HCC cells. A. Effect of increasing concentrations of 
tivantinib on cell viability as judged by Sybr green assays in the indicated cell lines. B. Colony forming assay showing number of colonies 
and representative figures of the indicated cell lines. Results are expressed as mean and standard deviation of 3 independent experiments 
each conducted in triplicate. *p < 0.01; #p < 0.05 vs. control treated cells. C. Western blot analysis of c-MET and p-c-MET in the indicated 
cell lines. D. Effect of tivantinib on phosphorylation status of c-MET in Huh7 and HepG2 cells after administration of the c-MET ligand 
HGF. For this experiment, cells were incubated with tivantinib for 24 hours; HGF was added at the concentration of 100 ng/ml for 
10 minutes before the cells were harvested.
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cellular transition at the G2/M checkpoint [15], was 
assessed. Western blot analysis showed a strong increase 
of Cyclin B1 as soon as 3 hours after incubation (Fig. 4B). 
To assess whether increase of Cyclin B1 is functionally 
related to the cycle arrest caused by tivantinib, cells were 
transfected  by  specific Cyclin B1-targeting  siRNA. As 
shown in Fig. 4C, silencing of Cyclin B1 prevented the 
G2/M cell cycle arrest (Fig. 4D) and significantly reduced 
the loss of cell viability caused by tivantinib (Fig. 4E). 
These data indicate that a Cyclin-B1 dependent G2/M cell 
cycle arrest concurs with the induction of apoptosis to 
determine the antineoplastic effect of tivantinib.
Figure 2: Tivantinib causes apoptosis by activating the mitochondrial apoptotic pathway. A and B. Quantification (A) and 
typical FACS patterns (B) of apoptotic cells based on the count of the cell fraction showing subdyploid DNA content (sub-G1 fraction) after 
propidium iodide staining. *p < 0.01; #p < 0.05 in comparison to control treated cells. C. Fluorescence microscopy features after Hoechst 
staining showing typical chromatin condensation and nuclear fragmentation of Huh7 cells. D and E. Assessment of caspase 3 cleavage by 
western blot (D) and of caspase 3/7 activation as determined by fluorimetric assessment in HepG2 cells after 24 hours (E). F. Time kinetic 
of the expression of different regulators of apoptosis was performed by incubating Huh7 or HepG2 cell lines for the indicated time.
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Figure 3: Mcl-1 and Bcl-xl play a functional role in determining the apoptotic effect of tivantinib. A. Effect of Caspase 8 
inhibition on tivantinib-mediated apoptosis. FACS analysis was performed to assess nuclear fragmentation 72 hours after administration of 
tivantinib in the presence or absence of the Caspase8 inhibitor Z-IETD-FMK. B. Effect of Mcl-1 and Bcl-xl silencing by co-transfection of 
specific siRNA oligonucleotide sequences in Huh7 cells on expression of Bcl-xl and Mcl-1 (each at the concentration of 50 nM); Medium 
or non-coding siRNA (Ctrl-siRNA) were used as control. C and D. FACS analysis of apoptosis (C), and cell viability (D) after transfection 
of siRNA targeting Mcl-1 and Bcl-xl. *p < 0.01, in comparison to cells transfected with non-coding siRNA.
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Figure 4: Tivantinib causes a Cyclin B1-dependent G2 cell cycle arrest. A.  Cell  cycle  quantification  and  typical  flow 
cytometry pattern of G2/M cell cycle arrest of the indicated HCC cell lines after incubation with tivantinib for 24 hours and PI staining. 
B. Time kinetic of Cyclin B1 activation. C. Effect of Cyclin B1 silencing by specific siRNA (Cyclin B1-siRNA) on Huh7 cells. Non-coding 
siRNA (Ctrl-siRNA) was used as control. D and E. Effect of Cyclin B1 silencing on cell cycle (D) and cell viability (E) of Huh7 cells. 
After overnight incubation, cells were transfected with Cyclin B1-targeting siRNA for 24 h, and then treated with tivantinib for 1 hour 
before harvesting. Cellular viability was assessed by MTS assay in Huh7 cells after 48 hours. #p < 0.05 vs. cell incubated in medium only 
or non-coding siRNA.
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The antiproliferative effect of tivantinib is 
independent of c-MET but affects targets 
downstream of c-MET
After describing Bcl-xl, Mcl-1 and Cyclin B1 as 
functional targets of tivantinib in determining apoptosis 
and cell cycle arrest, we assessed whether the influence of 
tivantinib on these molecules is dependent on its efficacy 
as inhibitor of c-MET, as the predictive significance of 
this receptor in clinical trials seems to suggest [2, 16]. 
To this aim, we assessed the effects of c-MET silencing 
by siRNA transfection  in Huh7 cells; additionally, we 
compared the effect of tivantinib on DLD1 cells, which 
express the native form of c-MET vs. that on syngenic 
DLD1 c-MET exon 16 KO cell lines, which express 
a  genetically  modified  variant  of  c-MET  lacking  the 
binding site of tivantinib. Silencing of c-MET by siRNA 
failed to increase apoptosis and cell cycle arrest in Huh7 
cells and only modestly affected cell viability in these 
cells (Fig. 5A–5D). We also observed that the effect of 
tivantinb on cell viability, cell cycle and apoptosis in 
DLD1 wild type (WT) cells was indistinguishable from 
that observed in two independent c-MET exon 16 knock 
out cell clones (KO1 and KO2) (Fig. 5E–5G). Western 
blot analysis of these DLD1 cell clones showed that the 
expression of Mcl-1 and Bcl-xl was reduced and that of 
Figure 5: The antineoplastic effect of tivantinib is not dependent on c-MET. A, B, C and D. Effect of c-MET silencing on the 
expression of c-MET (A) on cell viability (B), apoptosis (C) and cell cycle (D), in Huh7 cells 72 hours after transfection of specific (c-MET-
siRNA) or non-coding siRNA (ctrl-siRNA). E, F, G, H and I. Effect of tivantinib on c-MET wild-type DLD1 colorectal cancer cell lines 
or in c-MET exon 16 knock-out DLD1 (two different clones) as determined by viability assay 6 days after incubation with tivantinib (E), 
assessment of apoptosis (F) and cell cycle analysis (G) 48 hours after incubation with tivantinib. Western Blot analysis (H) of Mcl-1 and 
Bcl-xl after 24 hours incubation with tivantinib andtime kinetic of Cyclin B1 activation (I) in these cell lines.
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Cyclin B1 increased in both wild type and c-MET-exon 
16 knock out DLD1 cells (Fig. 5H and 5I) upon incubation 
with tivantinib. The biological effects of tivantinb and 
the associated molecular changes observed in Huh7 and 
HepG2 cell lines were thus reproducible in 2 additional 
cell clones derived from DLD1 colorectal cancer cells 
and were independent of the expression of c-MET; this 
suggests that the antineoplastic activity of tivantinib is 
largely independent of its effect on this receptor.
We subsequently hypothesized that the significance 
of c-MET as predictor of the outcome of patients on 
tivantinib may be related to the fact that Mcl-1, Bcl-xl or 
Cyclin B1 are downstream targets of c-MET, and that the 
efficacy  of  tivantinib  in  tumors  overexpressing  c-MET 
may reflect the effect of this compound on c-MET-driven 
overexpression of these molecules.
To assess this possibility, a time kinetic of c-MET, 
Bcl-xl, Mcl-1 and Cyclin B1 expression was performed 
in Huh7 and HepG2 cells after incubation with HGF, 
which is the only known ligand of c-MET. This analysis 
showed that activation of c-MET leads to increased 
phosphorylation of c-MET (Tyr1349) and to increased 
Mcl-1 and Bcl-xl. However, a slight increase of Cyclin B1 
could also be observed upon c-MET stimulation (Fig. 6). 
These data show that while tivantinib might antagonize the 
effect of c-MET-mediated expression of Mcl-1and Bcl-xl, 
the effect of tivantinib Cyclin B1 might not be predictable 
by the expression of c-MET.
DISCUSSION
c-MET inhibitors are considered a promising 
therapeutic option for tumours exhibiting c-MET-status 
alterations [17]. Tivantinib prolonged time-to-progression 
and overall survival among c-MET diagnostic-high HCC 
patients as a second line treatment after failure of a first 
line sorafenib treatment [2, 3] Therefore, only patients 
selected according to a “c-MET-high” status are recruited 
in the ongoing phase-3 study of tivantinib in HCC [3]. 
Unexpectedly, the concept of tivantinib as c-MET inhibitor 
has been recently challenged, and it has been suggested 
that c-MET might represent a predictor of efficacy rather 
than the actual target of this compound [6–9]. In this 
paper we addressed this issue 1) by investigating the so 
far unknown molecular mechanisms underlying apoptosis 
and cell cycle induced by tivantinib and 2) by assessing 
whether  these effects  are  specifically dependent on  the 
effect of tivantinib on c-MET. These topics and their 
clinical implications are discussed below.
Molecular mechanisms underlying the effect of 
tivantinib on apoptosis and cell cycle
 Since tivantinib was previously shown to induce 
apoptosis and G2/M-cell cycle arrest, we first assessed its 
effect on crucial mechanisms of apoptosis and cell cycle 
control. Assessment of apoptosis showed that tivantinb 
causes cleavage of Procaspase-8 followed by the cleavage 
of Bid. Cleavage of Caspase 8 is a hallmark of the activation 
of the extrinsic apoptotic pathway, which is initiated at the 
cell membrane in consequence of the stimulation of the 
“death-receptors” such as TRAIL-R1 and –R2 or CD95. 
Accordingly, administration of tivantinib sensitized several 
cancer cell lines to the action of the TRAIL-R2 agonistic 
antibody tigatuzumab (Fig. S4). Nevertheless, inhibition 
of Caspase 8 only marginally affected apoptosis induced 
by tivantinib indicating that activation of the extrinsic 
signalling pathway plays a marginal role in triggering 
apoptosis observed in our system.
As we assessed the effect of tivantinib on the 
intrinsic signaling pathway we observed a strong decrease 
of the antiapoptotic proteins Bcl-xl and Mcl-1. The 
intrinsic pathway is regulated by the balance between 
pro-apoptotic molecules (such as Bax, Bak, Bim and 
Bid) and antiapoptotic molecules (such as Bcl-2, Bcl-xl 
and Mcl-1). Mcl-1 and Bcl-xl are Bcl-2-related proteins 
which bind to Bax and Bak, thereby blocking their 
pro-apoptotic interaction with the outer surface of the 
mitochondria [18]. The functional relevance of Bcl-xl and 
Mcl-1 in determining apoptosis mediated by tivantinib 
was  confirmed  by  si-RNA  against  Bcl-xl  and  Mcl-1 
which caused apoptosis to an extent comparable with 
that observed upon tivantinib administration. The effect 
on Mcl-1 of tivantinib on Mcl-1 is in keep with previous 
findings  showing  that  CKD  inhibitors  trigger  apoptotic 
cell death by inhibiting Mcl-1 [19]. These data show that 
Figure 6: Mcl-1 and Bcl-xl are regulated by stimulation of c-MET. Time kinetic of phospho-MET, Mcl-1, Bcl-xl and Cyclin B1 at 
western blot analysis. Huh7 and HepG2 cells were incubated with 10 ng/ml human recombinant HGF and collected at the indicated time points.
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while cleavage of Caspase 8 and activation of the extrinsic 
apoptotic pathway might play a role in determining the 
effect of tivantinib in vivo e.g. by affecting the response to 
endogenous TRAIL, tivantinib causes apoptosis principally 
by shifting the balance between the mediators of the 
mitochondrial pathway by inhibiting Bcl-xl and Mcl-1.
In addition, we observed a strong increase of Cyclin 
B1 as soon as 3 hours after administration of tivantinib. 
Cyclin B1 controls the G2-M cell cycle transition [20, 21] 
and its elevation was shown to cause mitotic delay in Hela 
cells [15, 22]. In agreement with these previous reports, 
we found that silencing of Cyclin B1 reversed the G2/M 
cell  cycle  arrest  caused  by  tivantinib  and  significantly 
reduced its effect on cell viability.
c-MET expression and response to tivantinib.
Experiments conducted with c-MET exon 16 KO 
DLD1 cell lines, which lack the tivantinib-binding site of 
c-MET, showed that the effect of tivantinib in these cell 
lines was indistinguishable from that observed in parental-
Wild Type DLD1 cell lines. Accordingly, tivantinib led to 
the downregulation of Bcl-xl, Mcl-1 and to the upregulation 
of Cyclin B1 independently of the c-MET status of these 
cell  clones.  Moreover,  silencing  of  c-MET  by  specific 
siRNA  failed  to  reproduce  the  effect  of  tivantinib  on 
apoptosis and cell cycle. Administration of tivantinib 
caused a decrement of total c-MET and, to the same extent, 
of its phosphorylated form, indicating that the decrease of 
overall c-MET largely accounts for the observed decrease 
of c-MET phosphorylation. Nevertheless, our results show 
that the antineoplastic activity of tivantinib is largely 
independent of its effect as c-MET inhibitor.
This discrepancy between our data and the predictive 
effect of c-MET expression in the clinical setting might 
be due to differences related to the higher complexity 
of the mechanisms of action of tivantinib in vivo, e.g. 
those underlying invasion and metastasis formation [23], 
and to microenvironmental changes related to previous 
administration of sorafenib in these patients. Such hypothesis 
would be supported by the reported role of c-MET in 
hypoxic conditions and in resistance to anti-angiogenic 
therapy  [24,  25].  Nevertheless,  the  remarkable  effect  of 
tivantinib on cell viability, cell cycle and apoptosis observed 
in our experiments suggests that these effects account for the 
antineoplastic effects of tivantinib observed in the clinical 
setting.
To  find  possible  explanations  for  the  predictive 
relevance of c-MET in clinical trials, we hypothesized 
that Bcl-xl, Mcl-1 and Cyclin B1 are downstream targets 
of c-MET, and that the efficacy of tivantinib on tumors 
overexpressing  c-MET  may  reflect  the  effect  of  this 
compound on c-MET-driven overexpression of these 
molecules. Stimulation of c-MET by HGF showed a clear 
increase of Bcl-xl and Mcl-1 suggesting that tivantinib 
might antagonize the effect of c-MET-dependent 
expression of these molecules in cells overexpressing this 
receptor regardless of the inhibitory effect of tivantinib on 
the kinase activity of c-MET.
Although the mechanisms by which tivantinib 
causes such molecular alterations still remains elusive, 
a possible answer to this issue might be provided by the 
recent works published by Basilico [6], Katayama [7], 
and their colleagues. These authors found that tivantinib 
exerted a cytotoxic effect in several cell lines without 
affecting the function of c-MET by causing microtubule 
stabilization or impairment of tubulin polymerization, 
respectively. Interestingly, microtubule-damaging agents 
are known to increase Cyclin B1 and to activate the 
spindle assembly checkpoint, and degradation of Mcl-1 
has been shown to occur as consequence of administration 
of microtubule-targeting agents [26]. It is thus likely 
Figure 7: Schematic diagram of the postulated interaction between tivantinib and intracellular mechanisms of 
apoptosis and cell cycle regulation.
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that tivantinib affects cell proliferation and apoptosis by 
impinging on microtubule formation and stability (Fig. 7).
In  summary,  we  identified  Bcl-xl,  Mcl-1  and 
Cyclin B1 as mediators of the antineoplastic effects of 
tivantinib. Our study provides a possible explanation for 
the preferential effect of tivantinib in c-MET-high patients 
but indicates that the beneficial clinical effect of tivantinib 
may not be predictable solely by c-MET, and prompts for 
the evaluation of the expression of other molecules, such 
as Mcl-1, Bcl-xl and Cyclin B1 as possible and potentially 
more reliable markers for patients’ selection.
MATERIALS AND METHODS
Cell lines culture and reagents
Huh7, HepG2, Hep3B, Chang cells (hepatocellular 
carcinoma), TFK1 (human cholangiocarcinoma), DLD1 
cells  (human  colon  carcinoma),  PL5  and  PANC1  cells 
(human pancreatic carcinoma) were used for in vitro 
experiments. DLD1 colorectal cancer cells and two 
different syngenic c-MET exon 16 knock-out DLD-1 
clones were provided by A. Bardelli and S. Arena and 
have been previously described [13]. All cell lines were 
cultivated in standard cell culture media as recommended 
by the providers. Tivantinib (ARQ197, provided by 
ArQule, Woburn MA, USA.) was dissolved in 100% 
DMSO and stored at −20°C. Tigatuzumab (CS-1008, by 
Daiichi Sankyo Pharma Development, Edison NJ, USA) 
was provided as a 10 mg/ml solution and stored at 4°C. 
Recombinant Human HGF was purchased from R&D 
(Minneapolis, MN USA).
Cell viability assay
Cells were seeded onto 96-well plates at different 
cell densities to avoid overgrowth (0.6–3.5 × 103/well) and 
were treated with increasing concentrations of tivantinib 
or vehicle. To investigate the effect of tivantinib on cell 
viability at low concentrations, cells were kept in culture for 
6 days. At day 6 cells were washed with PBS, underwent 
osmotic-lysis in 100 μl ddH2O, and then incubated in 5% 
CO2 incubator for 45 minutes. Fluorescence was measured 
after addition of 0.2% Sybr green (Cytoflour Series 4000, 
Applied Biosystems, Framingham, MA USA).
Colony formation assay
4–5 × 103 cells were plated onto 6-well plates. 
After 24-h incubation with tivantinib cells were allowed 
to grow for 3 weeks. Colony formation was evaluated 
after  the  cells  were  fixed  in  9%  paraformaldehyde 
and stained with crystal violet for 30 minutes (Sigma, 
St. Louis, MO USA). Total cell colonies in each well 
were counted after being photographed.
Apoptosis and cell cycle assay
8.0 × 104−1.5  ×  105 cells were seeded in 
12-well plates and treated after overnight incubation. 
Fluorescence activated cell sorting (FACS– 
Accuri-C6 flow cytometer, BD Biosciences San Jose, CA 
USA) was performed to detect the sub-G1 cell fraction 
to determine apoptosis and the respective different 
phases of cell cycle after propidium iodide (PI) staining 
as previously described [27]. In addition, apoptosis was 
assessed morphologically by Hoechst 33342 staining 
and fluorescence microscopy.
Western blot and caspase activity assays
Cells growing in Petri dishes were collected 
and lysed in cell lysis buffer (Cell Signaling 
Technology, Boston MA USA) containing 20 mmol/L 
Tris-HCL  (PH7.5),  150  mmol/L  NaCl,  1  mmol/L 
Na2EDTA, 1 mmol/L EGDA, 1% Triton, 2.5 mmol/L 
sodium pyrophosphate, 1 mmol/L β-glycerophosphate, 
1 mmol/L Na3VO4, 1 μg/ml  leupeptin,  and 1 mmol/l 
phenylmethane  sulphonyl  fluoride.  Membranes  were 
incubated  overnight  at  4°C  with  specific  antibodies 
in TBS-T (TBS-0.1% Tween20) and subsequently for 
one hour with the appropriate horseradish-peroxidase-
conjugated anti-rabbit/mouse secondary antibody. 
The following mouse monoclonal antibodies were 
used: Anti-CyclinB1 (Santa Cruz Biotechnology, 
Dallas  Texas  USA),  anti-Caspase-8,  anti-β-actin 
(both from Cell Signaling Technology, Boston MA 
USA). The following rabbit polyclonal antibodies 
were used: anti-Caspase-3, anti-PARP, anti-Bid, anti-
Bad, anti-Bcl-2, anti-Bcl-xl, anti-Bax, anti-Mcl-1 (all 
from Cell Signaling Technology), anti-c-MET, anti-
phosphorylated c-MET (Tyr1349 and Tyr1234/1235). 
For Caspase-3/7 activity assays the Apo-ONE® Reagent 
kit (Promega, Madison WI USA) was used according 
to the instructions of the manufacturer. Actin was 
used for control of appropriate protein load for each 
membrane. In figures, one actin loading control has been 
exemplarily shown.
Small interfering RNA and transfection
Cyclin B1, Bcl-xl, Mcl-1 and c-MET 
were  silenced  by  small  interfering  RNA  (siRNA)  or 
non-coding  siRNA.  Specific  siRNA  SMARTpool® 
sequences  consist  of  4  pooled  21-nucleotide  RNA 
oligonucleotides forming a 19-bp duplex core with 
2-nucleotide 3 overhang and were purchased from 
Dharmacon, Inc. (Thermo Scientific, Rockford IL USA). 
For transfection the DharmaFECT4 reagent (Thermo 
Scientific, Rockford IL USA) was used according to the 
manufacturer’s instructions.
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Statistical analysis
Statistical analysis was performed by using IBM 
SPSS Statistics (SPSS Inc, IL USA). Comparison of 
means was performed by two-tailed Student’s test. Results 
are expressed as mean and standard deviation (SD) of at 
least 3 independent experiments. P values < 0.05 were 
regarded as statistically significant.
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